A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia

被引：4

作者：

Parrondo, Ricardo D. ^{[1
]}

Dutta, Navnita ^{[2
]}

Laplant, Betsy R. ^{[3
]}

Elliott, Jamie ^{[1
]}

Fernandez, Andre ^{[1
]}

Zimmerman, Ashley ^{[1
]}

Cicco, Gina ^{[2
]}

Han, Bing ^{[2
]}

Heslop, Keisha ^{[1
]}

Chapin, Dustin ^{[1
]}

Sher, Taimur ^{[1
]}

Roy, Vivek ^{[1
]}

Rasheed, Ahsan ^{[1
]}

Das, Saurav ^{[1
]}

Chanan-Khan, Asher A. ^{[1
,2
]}

Paulus, Aneel ^{[2
]}

Ailawadhi, Sikander ^{[1
,2
,4
]}

机构：

[1] Mayo Clin, Canc Ctr, Jacksonville, FL USA

[2] Mayo Clin, Dept Canc Biol, Jacksonville, FL USA

[3] Mayo Clin, Quantitat Hlth Sci, Rochester, MN USA

[4] Mayo Clin, Div Hematol Oncol, 4500 San Pablo Rd, Mangurian Bldg 3rd Floor, Jacksonville, FL 32224 USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2024年 / 204卷 / 05期

关键词：

clinical trials; non Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia; WALDENSTROM MACROGLOBULINEMIA; RITUXIMAB; DEXAMETHASONE; ZANUBRUTINIB; THERAPY;

D O I：

10.1111/bjh.19320

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This phase II study evaluated time-limited (24 cycles) treatment with ibrutinib and ixazomib in newly diagnosed (NDWM; n = 9) and relapsed/refractory (RRWM; n = 12) Waldenstrom macroglobulinaemia (WM). The overall response rate (ORR) was 76.2% (n = 16) in 21 evaluable patients with no patient achieving a complete response (CR). The median duration of treatment was 15.6 months, and after a median follow-up time of 25.7 months, the median progression-free survival (PFS) was 22.9 months. While the primary end-point was not met (CR rate at any time) and 28.5% discontinued treatment due to toxicity, ibrutinib plus ixazomib led to a clinically meaningful ORR and PFS. Combined Bruton's tyrosine kinase (BTK) and proteasome inhibition merits further evaluation in WM.

引用

页码：1825 / 1829

页数：5

共 50 条

[31] A phase 1/2 study of ixazomib in place of bortezomib or carfilzomib in a subsequent line of therapy for patients with multiple myeloma refractory to their last bortezomib or carfilzomib combination regimen [J].

Daniely, David ;

Forouzan, Eli ;

Spektor, Tanya M. ;

Cohen, Alexa ;

Bitran, Jacob D. ;

Chen, Gigi ;

Moezi, Mehdi M. ;

Bessudo, Alberto ;

Hrom, John ;

Eshaghian, Shahrooz ;

Swift, Regina A. ;

Eades, Benjamin M. ;

Kim, Clara ;

Lim, Stephen ;

Berenson, James R. .

EXPERIMENTAL HEMATOLOGY, 2022, 111 :79-86

[32] Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study [J].

Gopal, Ajay K. ;

Schuster, Stephen J. ;

Fowler, Nathan H. ;

Trotman, Judith ;

Hess, Georg ;

Hou, Jing-Zhou ;

Yacoub, Abdulraheem ;

Lill, Michael ;

Martin, Peter ;

Vitolo, Umberto ;

Spencer, Andrew ;

Radford, John ;

Jurczak, Wojciech ;

Morton, James ;

Caballero, Dolores ;

Deshpande, Sanjay ;

Gartenberg, Gary J. ;

Wang, Shean-Sheng ;

Damle, Rajendra N. ;

Schaffer, Michael ;

Balasubramanian, Sriram ;

Vermeulen, Jessica ;

Cheson, Bruce D. ;

Salles, Gilles .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (23) :2405-+

[33] Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer [J].

Kwon, Minsuk ;

Kim, Gahyun ;

Kim, Ryul ;

Kim, Kyu-Tae ;

Kim, Seung Tae ;

Smith, Simon ;

Mortimer, Peter G. S. ;

Hong, Jung Yong ;

Loembe, Arsene-Bienvenu ;

Irurzun-Arana, Itziar ;

Koulai, Loumpiana ;

Kim, Kyoung-Mee ;

Kang, Won Ki ;

Dean, Emma ;

Park, Woong-Yang ;

Lee, Jeeyun .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (07)

[34] Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer [J].

Nole, Franco ;

Crivellari, D. ;

Mattioli, R. ;

Pinotti, G. ;

Foa, P. ;

Verri, E. ;

Fougeray, R. ;

Brandely, M. ;

Goldhirsch, A. .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (04) :673-680

[35] Phase II study of chidamide in combination with cisplatin in patients with metastatic triple-negative breast cancer [J].

Meng, Yanchun ;

Jin, Juan ;

Gong, Chengcheng ;

Miao, Haitao ;

Tao, Zhonghua ;

Li, Ting ;

Cao, Jun ;

Wang, Leiping ;

Wang, Biyun ;

Zhang, Jian ;

Hu, Xichun .

ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (11) :11255-11264

[36] A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma [J].

Rini, B. ;

Redman, B. ;

Garcia, J. A. ;

Burris, H. A., III ;

Li, S. ;

Fandi, A. ;

Beck, R. ;

Jungnelius, U. ;

Infante, J. R. .

ANNALS OF ONCOLOGY, 2014, 25 (09) :1794-1799

[37] Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma [J].

Lee, Hun Ju ;

Romaguera, Jorge E. ;

Feng, Lei ;

Desai, Aakash P. ;

Zhang, Liang ;

Fanale, Michelle ;

Samaniego, Felipe ;

Hagemeister, Fredrick B. ;

Fayad, Luis E. ;

Rodriguez, Maria A. ;

Medeiros, Jeffrey L. ;

Hartig, Kimberly ;

Nomie, Krystle ;

Ahmed, Makhdum ;

Badillo, Maria ;

Ye, Haige ;

Oki, Yasuhiro ;

Lin, Pei ;

Nastoupil, Loretta ;

Westin, Jason ;

Wang, Michael .

ONCOLOGIST, 2017, 22 (05) :549-553

[38] Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study [J].

Davids, Matthew S. ;

Kim, Haesook T. ;

Nicotra, Alyssa ;

Savell, Alexandra ;

Francoeur, Karen ;

Hellman, Jeffrey M. ;

Bazemore, Josie ;

Miskin, Hari P. ;

Sportelli, Peter ;

Stampleman, Laura ;

Maegawa, Rodrigo ;

Rueter, Jens ;

Boruchov, Adam M. ;

Arnason, Jon E. ;

Jacobson, Caron A. ;

Jacobsen, Eric D. ;

Fisher, David C. ;

Brown, Jennifer R. .

LANCET HAEMATOLOGY, 2019, 6 (01) :E38-E47

[39] Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study [J].

Younes, Anas ;

Brody, Joshua ;

Carpio, Cecilia ;

Lopez-Guillermo, Armando ;

Ben-Yehuda, Dina ;

Ferhanoglu, Burhan ;

Nagler, Arnon ;

Ozcan, Muhit ;

Avivi, Irit ;

Bosch, Francesc ;

Caballero Barrigon, Maria Dolores ;

Hellmann, Andrzej ;

Kuss, Bryone ;

Ma, David D. F. ;

Demirkan, Fatih ;

Yagci, Munci ;

Horowitz, Netanel A. ;

Marlton, Paula ;

Cordoba, Raul ;

Wrobel, Tomasz ;

Buglio, Daniela ;

Streit, Michael ;

Hodkinson, Brendan P. ;

Schaffer, Michael ;

Alvarez, John ;

Ceulemans, Rob ;

Balasubramanian, Sriram ;

de Jong, Jan ;

Wang, Shean-Sheng ;

Fourneau, Nele ;

Jurczak, Wojciech .

LANCET HAEMATOLOGY, 2019, 6 (02) :E67-E78

[40] Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study [J].

Kumar, Shaji K. ;

Berdeja, Jesus G. ;

Niesvizky, Ruben ;

Lonial, Sagar ;

Laubach, Jacob P. ;

Hamadani, Mehdi ;

Stewart, A. Keith ;

Hari, Parameswaran ;

Roy, Vivek ;

Vescio, Robert ;

Kaufman, Jonathan L. ;

Berg, Deborah ;

Liao, Eileen ;

Di Bacco, Alessandra ;

Estevam, Jose ;

Gupta, Neeraj ;

Hui, Ai-Min ;

Rajkumar, Vincent ;

Richardson, Paul G. .

LANCET ONCOLOGY, 2014, 15 (13) :1503-1512

← 1 2 3 4 5 →